Evotec Announced Progress Within Its Partnership With Bristol Myers Squibb Relating To Building A Molecular Glue-based Pipeline. Performance And Program-based Achievements Trigger $75M To Evotec
Author: Benzinga Newsdesk | March 16, 2023 04:40am
Evotec and Bristol Myers Squibb entered their strategic protein degradation partnership in 2018 and expanded it in May of 2022, because of the highly productive initial collaboration generating a promising pipeline.
Since the expansion, Evotec has significantly scaled up its activities to develop highly promising compounds from Bristol Myers Squibb's industry-leading library of cereblon E3 ligase modulators (CELMoDs).
The partnership continues to deliver on its goal to build a leading pipeline of novel molecular glue degraders, targeting high-value targets in the field of oncology and beyond.